Opinion|Videos|September 10, 2025
Exploring Ritlecitinib for Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Ungar: Ritlecitinib is the first and only treatment approved by the FDA, in 2023, for adolescents (age 12 and older+) with severe AA. What are its distinct properties compared to other JAK inhibitors that contribute to the potential use in adolescents?
- How does the introduction of a pediatric treatment option influence your treatment decision?
- Where does this leave ritlecitinib in the treatment algorithm for AA
- How do you deal with the drug-to-drug interactions associated with this therapy?
Advertisement
Related to this article
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5